REGENXBIO, Inc. (RGNX)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
-25.33% vs
Rating Accuracy
0% (0 of 1*)
FV Performance
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+0.0%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+0.0%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+5.01%
FV Accuracy
9 Hits (20.93% Hit Rate)
FV Avg. Distance
+27.34%
About
CEO
Kenneth T. Mills
Employees
257
Industry
Neurology Biopharmaceuticals
Sector
Healthcare
Headquarters
Rockville
Exchange
NASDAQ
Website
http://www.regenxbio.comSummary Stats
Market Cap
988M
Revenue
484M
Net Income
90.7M
EPS
$2.05
Price-to-Earnings
11.15
Price-to-Book
1.57
Debt-to-Equity
0.51
News
Analyst Ratings
Price targets projected by 8 analysts
High
$100.00
Average
$57.50
Low
$31.00
Ratings calculated by 8 analysts
Buy
6
Hold
2
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q2 2022
Missed by -$0.05
-$1.58 -3.3%
-1.53
-1.36
Down 16%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--